Condition
aHUS
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 4 (1)
Trial Status
Completed2
Terminated1
Recruiting1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07308574Phase 4RecruitingPrimary
Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS
NCT05405777CompletedPrimary
A Retrospective Study to Evaluate the Clinical Outcome According to Treatment in aHUS Patients in South Korea
NCT04725812Phase 2Terminated
Complement Regulation to Undo Systemic Harm in Preeclampsia
NCT04749810Completed
Observational Study of Elizaria® in aHUS Patients
Showing all 4 trials